Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 10, 2007

Novartis Prolongs Market Exclusivity for High Blood Pressure Medication by Six Months

  • Novartis received an additional six months of market exclusivity for its high blood pressure drug, Diovan. The treatment is indicated for use in adults with high blood pressure and heart failure, as well as heart attack survivors.

    This extension, which takes patent expiration to September 2012, was based on studies conducted in children with high blood pressure. Novartis says that high blood pressure is reported in 5% of children and adolescents in the U.S. An FDA decision on a possible indication to treat children and adolescents with high blood pressure is anticipated by year end.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »